---
title: "Hunan Jiudian Pharmaceutical Co., Ltd. (300705.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/300705.SZ.md"
symbol: "300705.SZ"
name: "Hunan Jiudian Pharmaceutical Co., Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-20T14:32:04.371Z"
locales:
  - [en](https://longbridge.com/en/quote/300705.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/300705.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/300705.SZ.md)
---

# Hunan Jiudian Pharmaceutical Co., Ltd. (300705.SZ)

## Company Overview

Hunan Jiudian Pharmaceutical Co., Ltd. researches, develops, produces, and sells pharmaceutical products in China and internationally. Its products portfolio includes Pantoprazole Sodium Enteric-coated, Ferrous Succinate, Rosuvastatin Calcium, Ebastine, and Rabeprazole Sodium Enteric-coated Tablets; and Acetylcysteine Granules, Potassium Sodium Hydrogen Citrate Granules, Loxoprofen Sodium Gel Patch, and Ketoprofen gel patch. The company also offers drugs for analgesic, cardio-cerebrovascular, anti-infection, digestive and urinary system, and breathing and anti-allergy.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.hnjiudian.com](https://www.hnjiudian.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:09.000Z

**Overall: B (0.36)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 42 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -0.85% |  |
| Net Profit YoY | -21.21% |  |
| P/B Ratio | 2.28 |  |
| Dividend Ratio | 2.54% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 6074313678.60 |  |
| Revenue | 3015469988.71 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 15.12% | A |
| Profit Margin | 13.41% | B |
| Gross Margin | 66.85% | A |
| Revenue YoY | -0.85% | D |
| Net Profit YoY | -21.21% | D |
| Total Assets YoY | 18.08% | A |
| Net Assets YoY | 7.24% | B |
| Cash Flow Margin | 143.06% | B |
| OCF YoY | -0.85% | D |
| Turnover | 0.79 | B |
| Gearing Ratio | 31.03% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Hunan Jiudian Pharmaceutical Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-0.85%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-21.21%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.28",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "2.54%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "6074313678.60",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "3015469988.71",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "15.12%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "13.41%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "66.85%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "-0.85%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "-21.21%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "18.08%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "7.24%",
          "rating": "B"
        },
        {
          "name": "Cash Flow Margin",
          "value": "143.06%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "-0.85%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "0.79",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "31.03%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 14.56 | 13/215 | 17.15 | 16.38 | 15.57 |
| PB | 2.22 | 100/215 | 3.37 | 3.05 | 2.82 |
| PS (TTM) | 1.95 | 31/215 | 2.78 | 2.61 | 2.43 |
| Dividend Yield | 2.61% | 45/215 | 2.07% | 1.93% | 1.80% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-12T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 11.75 |
| Highest Target | 29.00 |
| Lowest Target | 29.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/300705.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/300705.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/300705.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/300705.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**